June 2026 Quarterly Activities Report and Appendix 4C
Open PDF
| Stock | Race Oncology Ltd (RAC.ASX) |
|---|---|
| Release Time | 28 Jul 2026, 9:12 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Race Oncology Ltd Q4 FY2026 Report
Key Points
- First patient treated in Phase 1 HARNESS-1 trial for EGFR-mutated NSCLC
- Presented new data on RC220's mechanism of action at AACR 2026
- CPACS trial cleared to escalate to next RC220 dose level
- Cash balance of $34.3 million, funding into CY2028
Full Summary
Race Oncology Ltd released its Q4 FY2026 report, highlighting significant progress in its RC220 clinical development strategy. The company presented new preclinical data at the AACR 2026 Annual Meeting, demonstrating RC220's ability to silence c-MYC gene expression. The Phase 1 CPACS trial advanced to the next RC220 dose level, and the first patient was treated in the Phase 1 HARNESS-1 trial for EGFR-mutated NSCLC. The company's cash balance of $34.3 million at 30 June 2026 provides funding into CY2028, ensuring continued execution of its clinical programs.
Guidance
Cash balance of $34.3 million, funding into CY2028
Outlook
Race Oncology Ltd is well-funded to advance its clinical programs into CY2028, with key milestones achieved in Q4 FY2026.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In